MISSISSIPPI COBRE: PROJ 1: MITRAGYNINE BASED OPIOID LIGANDS
密西西比 COBRE:项目 1:基于帽柱木碱的阿片类配体
基本信息
- 批准号:7959627
- 负责人:
- 金额:$ 19.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-07-01 至 2010-06-30
- 项目状态:已结题
- 来源:
- 关键词:7-hydroxymitragynineAgonistAnalgesicsBehavioral ParadigmBindingBiological FactorsCenters of Research ExcellenceComputer Retrieval of Information on Scientific Projects DatabaseDevelopmentFundingGrantInstitutionInvestigationKnowledgeLigand BindingLigandsMediatingMedicinal HerbsMississippiMitragynaMolecularMolecular ModelsOpioidOpioid ReceptorProceduresReportingResearchResearch PersonnelResourcesRoleSourceStructureTherapeuticUnited States National Institutes of HealthWorkanalogbasechemical synthesisdesignimprovedin vivoinsightinterestmolecular modelingnovelopioid abusepharmacophore
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
Mitragynine is a mu-selective opioid agonist isolated from the Thai traditional medicinal herb, Mitragyna speciosa. Recent studies have suggested this compound, and the reported analogs, posses analgesic activity mediated through opioid receptors. However, the novel structural class makes them interesting from a structural comparison standpoint to known mu and opioid ligands. The work planned here, examines the molecular basis of mitragynine recognition and binding to the opioid receptors using a combination of chemical synthesis, molecular modeling, and ligand binding studies and in vivo behavioral paradigms. We hypothesize that the structure of mitragynine can be utilized as a template for the design and synthesis of subtype-selective opioid receptor ligands and through elucidation of the pharmacophore, structurally novel synthetic opioid ligands can be realized. Accomplishing such will greatly improve the knowledge of interactions of these structurally novel compounds with opioid receptors and facilitate the development and understanding of the potential therapeutic roles of these ligands. This work will be accomplished by: 1) optimizing the extraction and purification procedures, 2) determining the molecular basis of mitragynine binding to opioid receptors, 3) identifying the pharmacophore of mitragynine and 7-hydroxymitragynine, and 4) investigating the in vivo activity of mitragynine and analogs. It is anticipated that the potential use of mitragynine as a new opioid template for the design of subtype selective ligands and their potential use for investigation as therapies for opiate abuse will be determined. Furthermore, this work will provide further insight into the mechanism of pharmacological activity of mitragynine and derivatives.
这个子项目是众多研究子项目之一
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christopher R McCurdy其他文献
Structure-Activity Relationship (SAR) Study of Rigid Guanidine and Guanidino-mimetic Analogues of the Neuropeptide FF Receptor Antagonist MES304 (preprint)
神经肽 FF 受体拮抗剂 MES304 的刚性胍和胍基模拟类似物的构效关系 (SAR) 研究(预印本)
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:0
- 作者:
Kareem A. Galal;Marco Mottinelli;C. Mesangeau;Sampa Gupta;Christopher R McCurdy;C. Mollereau - 通讯作者:
C. Mollereau
Christopher R McCurdy的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Christopher R McCurdy', 18)}}的其他基金
Kratom alkaloids: in vitro and in vivo pharmacological mechanisms
卡痛生物碱:体外和体内药理机制
- 批准号:
10754688 - 财政年份:2019
- 资助金额:
$ 19.69万 - 项目类别:
Kratom alkaloids: in vitro and in vivo pharmacological mechanisms
卡痛生物碱:体外和体内药理机制
- 批准号:
10570897 - 财政年份:2019
- 资助金额:
$ 19.69万 - 项目类别:
Kratom alkaloids: in vitro and in vivo pharmacological mechanisms
卡痛生物碱:体外和体内药理机制
- 批准号:
10117220 - 财政年份:2019
- 资助金额:
$ 19.69万 - 项目类别:
Kratom alkaloids: in vitro and in vivo pharmacological mechanisms
卡痛生物碱:体外和体内药理机制
- 批准号:
10493516 - 财政年份:2019
- 资助金额:
$ 19.69万 - 项目类别:
Kratom alkaloids: in vitro and in vivo pharmacological mechanisms
卡痛生物碱:体外和体内药理机制
- 批准号:
9764570 - 财政年份:2019
- 资助金额:
$ 19.69万 - 项目类别:
Kratom alkaloids: in vitro and in vivo pharmacological mechanisms
卡痛生物碱:体外和体内药理机制
- 批准号:
9913489 - 财政年份:2019
- 资助金额:
$ 19.69万 - 项目类别:
Kratom alkaloids: in vitro and in vivo pharmacological mechanisms
卡痛生物碱:体外和体内药理机制
- 批准号:
10364662 - 财政年份:2019
- 资助金额:
$ 19.69万 - 项目类别:
Opioid use disorders: UF Pharmacy medications discovery and development
阿片类药物使用障碍:UF Pharmacy 药物的发现和开发
- 批准号:
10510803 - 财政年份:2018
- 资助金额:
$ 19.69万 - 项目类别:
Opioid use disorders: UF Pharmacy medications discovery and development
阿片类药物使用障碍:UF Pharmacy 药物的发现和开发
- 批准号:
10303378 - 财政年份:2018
- 资助金额:
$ 19.69万 - 项目类别:
Opioid use disorders: UF Pharmacy medications discovery and development
阿片类药物使用障碍:UF Pharmacy 药物的发现和开发
- 批准号:
10403754 - 财政年份:2018
- 资助金额:
$ 19.69万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 19.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 19.69万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 19.69万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 19.69万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 19.69万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 19.69万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 19.69万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 19.69万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 19.69万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 19.69万 - 项目类别: